We're talking about developing therapeutics for anti-aging. Matt Burns interviewed James Peyer, the co-founder of Cambrian BioPharma, and Maryanna Saenko, co-founder and partner at Future Ventures. Cambrian BioPharma bills itself as a new pharmaceutical company with a revolutionary approach to developing and managing drug development and raised over $180 million to accelerate the development of medicine designed to target the causes of age-related diseases.
Matt Burns spoke to James Peyer, the co-founder of Cambrian BioPharma, and Maryanna Saenko, co-founder and partner at Future Ventures. Cambrian BioPharma is a new pharmaceutical startup with a revolutionary approach to developing and managing drug development age-related diseases.
What we're most interested in, though, is how Cambrian’s executive team attracts and retains top talent. (Spoiler: They give them an oversized amount of equity compared to traditional pharmaceutical companies.)
James and Maryanna spoke to us about:
We closed out the show with a new batch of founders for Pitch Practice. And as always, if you want to check out the full video of today's conversation, head to our YouTube channel and stay tuned for more TechCrunch Live!
The TechCrunch Live Podcast drops at 6:00 a.m. PT every Monday, so subscribe to us on Apple Podcasts, Overcast,Spotify and all the casts.